<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940742</url>
  </required_header>
  <id_info>
    <org_study_id>17102</org_study_id>
    <secondary_id>I8F-MC-GPGQ</secondary_id>
    <nct_id>NCT03940742</nct_id>
  </id_info>
  <brief_title>A Study of Tirzepatide in Participants With Impaired Liver Function</brief_title>
  <official_title>A Single Dose Pharmacokinetic Study of Tirzepatide in Subjects With Varying Degrees of Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess how fast tirzepatide gets into the blood stream and&#xD;
      how long it takes the body to remove it in participants with impaired liver function compared&#xD;
      to healthy participants. The study will last about two months and will include five visits to&#xD;
      the study center.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Actual">September 22, 2020</completion_date>
  <primary_completion_date type="Actual">September 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of Tirzepatide</measure>
    <time_frame>Predose through 336 hours postdose</time_frame>
    <description>PK: AUC(0-∞) of Tirzepatide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Observed Drug Concentration (Cmax) of Tirzepatide</measure>
    <time_frame>Predose through 336 hours postdose</time_frame>
    <description>PK: Cmax of Tirzepatide</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hepatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>Tirzepatide Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide administered subcutaneously (SC) to participants with normal hepatic function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirzepatide Mild</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide administered SC to participants with mild hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirzepatide Moderate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide administered SC to participants with moderate hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirzepatide Severe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide administered SC to participants with severe hepatic impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirzepatide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Tirzepatide Control</arm_group_label>
    <arm_group_label>Tirzepatide Mild</arm_group_label>
    <arm_group_label>Tirzepatide Moderate</arm_group_label>
    <arm_group_label>Tirzepatide Severe</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All Participants:&#xD;
&#xD;
          -  Women of childbearing potential are excluded from the study.&#xD;
&#xD;
          -  Women not of childbearing potential may participate and include those who are&#xD;
             infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or&#xD;
             tubal ligation), congenital anomaly such as mullerian agenesis; or postmenopausal&#xD;
&#xD;
          -  Are between the body mass index (BMI) of 19.0 and 40.0 kilograms per meter squared&#xD;
             (kg/m²), inclusive, at screening&#xD;
&#xD;
        Healthy Participants:&#xD;
&#xD;
        - Healthy males or females as determined by medical history, physical examination, and&#xD;
        other screening procedures, with normal liver function&#xD;
&#xD;
        Participants with Impaired Liver Function:&#xD;
&#xD;
          -  Males or females with chronic mild, moderate and severe liver impairment, assessed by&#xD;
             Child-Pugh scoring&#xD;
&#xD;
          -  Have type 2 diabetes mellitus (T2DM) controlled with diet or exercise alone or on&#xD;
             stable doses of metformin for at least 8 weeks&#xD;
&#xD;
          -  Have a hemoglobin A1c (HbA1c) ≥6.0% and ≤11.0% at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All Participants:&#xD;
&#xD;
          -  Have known allergies to tirzepatide or related compounds&#xD;
&#xD;
          -  Have a personal or family history of medullary thyroid carcinoma or have multiple&#xD;
             endocrine neoplasia syndrome type 2&#xD;
&#xD;
          -  Have a history or presence of pancreatitis (history of chronic pancreatitis or&#xD;
             idiopathic acute pancreatitis), elevation in serum amylase or lipase or GI disorder&#xD;
             (eg, relevant esophageal reflux or gall bladder disease) or any GI disease which&#xD;
             impacts gastric emptying (eg, gastric bypass surgery, pyloric stenosis, with the&#xD;
             exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1)&#xD;
             analogs or dipeptidyl peptidase IV (DPP-IV) inhibitors&#xD;
&#xD;
        Participants with Impaired Liver Function:&#xD;
&#xD;
          -  Have hemoglobin &lt;8.5 grams per deciliter (g/dL)&#xD;
&#xD;
          -  Have kidney function that is significantly impaired at screening&#xD;
&#xD;
          -  Have taken any glucose-lowering medications other than metformin, including insulin,&#xD;
             in the past 3 months before screening&#xD;
&#xD;
          -  Have brain function impaired significantly due to liver condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/adult-type-2-diabetes/GPGQ#?postal=</url>
    <description>A Study of Tirzepatide in Participants With Impaired Liver Function</description>
  </link>
  <verification_date>October 1, 2020</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tirzepatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

